ANP (Atrial Natriuretic Peptide)
Also known as: Atrial Natriuretic Factor, ANF, Carperitide, Atriopeptin
Overview
Atrial Natriuretic Peptide (ANP) is a 28-amino acid peptide hormone released from cardiac atria in response to increased atrial pressure and volume overload. As the first natriuretic peptide identified (1981 by de Bold et al.), ANP established the concept of the heart as an endocrine organ. Carperitide, the synthetic recombinant ANP, is approved and widely used in Japan for acute heart failure, where it has accumulated substantial clinical evidence. ANP also has roles in regulating lipolysis, reducing inflammation, and suppressing the renin-angiotensin-aldosterone system.
Mechanism of Action
ANP binds natriuretic peptide receptor A (NPR-A) on vascular endothelial and smooth muscle cells, renal tubules, and adrenal gland, generating cGMP via guanylyl cyclase activity. cGMP-PKG signaling produces vasodilation, inhibits aldosterone and renin release, increases renal sodium and water excretion (natriuresis), and reduces sympathetic nervous system tone. In adipocytes, ANP activates PKA/HSL-mediated lipolysis via NPR-A and also through cGMP cross-activation of PKA. ANP is cleared primarily by NPR-C (clearance receptor) and neprilysin enzymatic degradation.
Potential Benefits
- Acute cardiac preload/afterload reduction
- Natriuresis and diuresis in heart failure
- Suppression of aldosterone and renin release
- Anti-fibrotic and anti-hypertrophic cardiac effects
- Adipocyte lipolysis stimulation
- Established therapeutic in Japan (Carperitide)
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Hospital use only |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | Acute use: 1-3 days |
Carperitide (recombinant human ANP) approved in Japan for acute HF. Not FDA-approved.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intravenous 100%
Hospital IV infusion only.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving ANP (Atrial Natriuretic Peptide):
Acute HF Management (Japan)
Japanese acute HF protocol.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. Use within 24 hours of reconstitution. |
|---|
Hospital preparation only.
Need exact syringe measurements?
Amino Acid Sequence
Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (cyclic via disulfide Cys7-Cys23)
Side Effects & Safety
- Hypotension (primary dose-limiting effect)
- Headache
- Compensatory renal effects with prolonged use
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~2-5 minutes |
|---|---|
| Storage | Refrigerate lyophilized product at 2-8°C. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside ANP (Atrial Natriuretic Peptide) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.